This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return ...

Johnson & Johnson JNJ announced that it has submitted a new drug application (NDA) to the FDA seeking approval for its ...

We thank Robert J van Soest and Roderick C N van den Bergh for their Correspondence about the prevention of severe genitourinary events in the PEACE-1 trial. In our trial, we used objective events (eg ...

This represents a potential first for preclinical evidence of anti-tumor activity by an efficacious BCL6-targeted small-molecule degrader in a human nTFHL-AI model. Furthermore, ARV-393 monotherapy ...

Arvinas PROTAC protein degraders have some potential, with vepdegestrant as its late-stage, most promising asset, partnered with Pfizer. Read more on ARVN here.

Arvinas' top executive, John Houston, plans to retire after roughly eight years at the helm of the clinical-stage biotechnology company. Arvinas on Wednesday said Houston, who has been president ...

– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor – – Dr. Houston to Remain Chairperson of Arvinas Board of ...

– Arvinas Board of Directors to Lead Search for CEO Replacement – NEW HAVEN, Conn., July 09, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company ...

NEW HAVEN, Conn., July 09, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, ...

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or ...

Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the company, MarketBeat reports ...